Program
Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112
Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, B-Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CRISPR Therapeutics | 22 open or running | phase 2since Aug 12, 2026 | Mar 25, 2025 | Dec 30, 2029phase 2 · NCT07804004 |
| CRISPR Therapeutics | 22 open or running | phase 2since Nov 30, 2022 | Nov 30, 2022 | Jan 2030phase 2 · NCT05643742 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2022First study: phase 2 study in Lymphoma, B-CellNew to CRISPR TherapeuticsCRISPR Therapeutics · NCT05643742 · 120 planned · United States, Australia
- Mar 25, 2025CRISPR Therapeutics’ first study: phase 1 study in Lupus Erythematosus, SystemicNew to CRISPR TherapeuticsCRISPR Therapeutics · NCT06925542 · 80 planned · United States, Germany, Spain
- Apr 8, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicCRISPR Therapeutics · NCT07549698 · 60 planned · United States, Germany, Spain
- Aug 12, 2026Phase 2 study in Multiple Sclerosis, Chronic ProgressivePhase 2 reachedCRISPR Therapeutics · NCT07804004 · 220 planned
Ahead
- Dec 30, 2029Primary completion: phase 2 study in Multiple Sclerosis, Chronic ProgressiveCRISPR Therapeutics · NCT07804004
- Jan 2030Primary completion: phase 2 study in Lymphoma, B-CellCRISPR Therapeutics · NCT05643742
- Dec 31, 2031Primary completion: phase 1 study in Lupus Erythematosus, SystemicCRISPR Therapeutics · NCT06925542
- Dec 2033Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicCRISPR Therapeutics · NCT07549698
TargetBeta
“A preparation of human allogeneic T-lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited with the clustered regularly interspaced short palindromic repeats (”NCIt, by rule
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07804004Multiple Sclerosis, Chronic Progressive | 2 | Not yet recruiting | CRISPR Therapeutics | Dec 30, 2029 | 220 |
| NCT07549698Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Spain | 2 | Recruiting | CRISPR Therapeutics | Dec 2033 | 60 |
| NCT06925542Lupus Erythematosus, Systemic · United States, Germany, Spain | 1 | Recruiting | CRISPR Therapeutics | Dec 31, 2031 | 80 |
| NCT05643742Lymphoma, B-Cell · United States, Australia | 2 | Recruiting | CRISPR Therapeutics | Jan 2030 | 120 |
How it is read
Names in the registry
- “CTX112”, 4 entries
Conditions, from the studies’ own filings
- Lupus Nephritis, 1 study
- Multiple Sclerosis, Chronic Progressive, 1 study
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.